Health and Healthcare

3 Hot Biotechs Highlight Jefferies Growth Stocks to Buy This Week

Lee Jackson

Published: April 5, 2016 9:55 am

Last Updated: January 13, 2020 11:09 am

After last week’s big run, the market took a breather Monday and looks poised for another one Tuesday. And all of Wall Street is handicapping what the first-quarter earnings will look like. With all the pre-announcements pretty much out and factored in, now it comes down to the actual numbers. We are in a stock picker’s market, so growth selection now is critical.

This week’s top U.S. growth calls from the analysts at Jefferies focus on companies that have some outstanding upside potential. While not suitable for conservative accounts, the Jefferies selections, which include the following three leading biotech stocks, look to be outstanding choices for aggressive investors.

Alder Biopharmaceuticals

This company is working on a migraine treatment that has big potential. Alder Biopharmaceuticals Inc. (NASDAQ: ALDR) is a clinical-stage biopharmaceutical company that discovers, develops and commercializes therapeutic antibodies in the United States and Australia. The company’s lead product candidate, ALD403, an antibody, is in Phase 2 clinical trials to target calcitonin gene-related peptide for the prevention of migraine.

Alder also develops ALD1613, which is in the preclinical stage, to treat patients with congenital adrenal hyperplasia and Cushing’s diseases, and clazakizumab, an antibody that has been completed Phase 2b clinical trial, which inhibits the pro-inflammatory cytokine interleukin-6 for the treatment of rheumatoid and psoriatic arthritis.

24/7 Wall St.
Merrill Lynch Adds Top Defense Stock to High Quality and Dividend Yield Screen